TTI Targets Multi-Billion Dollar Markets, Advancing Trials Thiogenesis Therapeutics Corp. (Ticker: TTI.v) is a clinical-stage biopharmaceutical company focused on developing thiol-active therapeutic compounds to address mitochondrial dysfunctions with high unmet medical needs.
A recent financial analysis from Valuation Lab, published on December 16, 2024, highlights the company’s lead compound, TTI-0102, and its potential across multiple pediatric and orphan indications.
https://www.valuationlab.com/research/
TTI-0102 is a prodrug designed to address limitations associated with cysteamine, a treatment for cystinosis. It is being developed for four key indications: MELAS, Leigh syndrome, Rett syndrome, and pediatric MASH.
These conditions represent significant market opportunities, with global peak sales projected to reach CAD 9.8 billion.
Key catalysts for 2025 include the start of Phase II proof-of-concept (POC) trials:
-
MELAS (Q1 2025): Potential peak sales of CAD 4 billion and a 15% projected success rate upon trial initiation, raising the risk-adjusted net present value (rNPV) by CAD 10.6 per share.
-
Leigh Syndrome (H1 2025): An ultra-rare condition with no approved treatments, projected peak sales of CAD 40 million, and a similar 15% success rate assumption, potentially increasing rNPV by CAD 0.1 per share.
-
Pediatric MASH (H1 2025): A larger market opportunity, with peak sales estimates of CAD 4 billion, and a projected rNPV increase of CAD 1.6 per share following trial commencement.
Valuation Lab assigns a risk-adjusted sum-of-parts valuation of CAD 7.5 per share, with MELAS accounting for 65% of this value.
Significant progress was made in 2024, including securing a European patent for TTI-0102 with protection until 2037, collaborations with research institutions, and regulatory approvals for clinical trials. These developments bolster the company’s intellectual property position and clinical readiness.
With plans to achieve break-even by 2026, Thiogenesis intends to commercialize orphan indications through contract sales organizations while seeking licensing deals for larger indications like pediatric MASH. This approach aims to maximize value while reducing upfront costs.
In summary, Thiogenesis Therapeutics is advancing TTI-0102 as a multi-indication pipeline with substantial market potential. Its focus on pediatric and orphan diseases, supported by strong intellectual property and expedited regulatory pathways, positions it for significant growth pending clinical milestones.
Download the full report here: https://www.valuationlab.com/app/download/8229158562/vL+Thiogenesis+Flash+Update+16DEC24.pdf
Posted on behalf of Thiogenesis Therapeutics Corp.